We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+11.52%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.05B
AUM Growth
+$69.9M
Cap. Flow
+$13.5M
Cap. Flow %
1.29%
Top 10 Hldgs %
49.49%
Holding
62
New
15
Increased
22
Reduced
15
Closed
8

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$28.7M
2
MOH icon
Molina Healthcare
MOH
+$27.6M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$26.9M
4
PRTA icon
Prothena Corp
PRTA
+$21.2M
5
NVRO
NEVRO CORP.
NVRO
+$18.2M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$48.6M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$45.2M
3
SAGE
Sage Therapeutics
SAGE
+$33.8M
4
AGN
Allergan plc
AGN
+$30.7M
5
PEN icon
Penumbra
PEN
+$21.8M

Sector Composition

Rank Sector Weight
1 Healthcare 73.5%
2 Financials 2.71%
3 Communication Services 2.42%
4 Industrials 0.75%
5 Consumer Staples 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
51
Aurinia Pharmaceuticals
AUPH
$1.94B
$79K 0.01%
28,410
+8,700
+44% +$23.8K
ADVM
52
DELISTED
Adverum Biotechnologies
ADVM
$70K 0.01%
+2,224
New +$100K
CSLT
53
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$41K ﹤0.01%
+10,229
New +$40.1K
DRRX
54
DELISTED
DURECT Corp
DRRX
– –
-232,714
Closed -$3.14M
IHF icon
55
iShares US Healthcare Providers ETF
IHF
$1.18B
– –
-22,600
Closed -$551K
PFE icon
56
Pfizer
PFE
$142B
– –
-130,485
Closed -$3.67M
SAGE
57
DELISTED
Sage Therapeutics
SAGE
– –
-1,053,018
Closed -$33.8M
CLVS
58
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-600,000
Closed -$11.5M
CCXI
59
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-10,000
Closed -$25K
GWPH
60
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-82,300
Closed -$5.94M
AGN
61
DELISTED
Allergan plc
AGN
– –
-114,448
Closed -$30.7M
1 2
3

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q2 2016 Portfolio in Review

As of Q2 2016, Redmile Group held 62 positions worth $1.05B, up 7.1% from $977M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q2 2016 filing shows 15 new, 22 increased, 15 reduced and 8 closed positions. Its largest new stake was Alexion Pharmaceuticals: 202,400 shares worth $23.6M. The largest sale was MEDIVATION, INC., an estimated $48.6M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 77% a quarter earlier, followed by Financials and Communication Services.

  • Redmile Group's largest Q2 2016 buy was Alexion Pharmaceuticals: 202,400 shares worth $23.6M.
  • Redmile Group added most to Molina Healthcare in Q2 2016, an estimated $27.6M increase.
  • Redmile Group's biggest Q2 2016 reduction was MEDIVATION, INC., cutting an estimated $48.6M.
  • Redmile Group fully exited Sage Therapeutics in Q2 2016, selling an estimated $33.8M.
  • Redmile Group's ten largest holdings make up 49% of its $1.05B portfolio in Q2 2016.
  • Redmile Group opened 15 new positions and closed 8 in Q2 2016.
  • Redmile Group's portfolio value rose 7.1% quarter-over-quarter to $1.05B.

Based on Redmile Group's 13F filing for Q2 2016, filed 16 Aug 2016.